2-fucosyllactose - Intrinsic Medicine
Alternative Names: 2-FL; OM-002Latest Information Update: 29 Sep 2023
At a glance
- Originator Intrinsic Medicine
- Class Anti-inflammatories; Behavioural disorder therapies; Oligosaccharides; Prebiotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Constipation; Diarrhoea; Inflammatory bowel diseases; Pervasive child development disorders
Most Recent Events
- 29 Sep 2023 University of Reading plans the PRInCE-UC clinical trial in Ulcerative colitis (In adults) (PO) in November 2023 (NCT06050811)
- 29 Nov 2022 Intrinsic Medicine plans a phase IIb trial for Constipation (Irritable bowel syndrome induced) in the first half of 2023 in Australia
- 14 Nov 2022 Chemical structure information added